Australia Pharmaceuticals & Healthcare Report Q3 2013 - New Report Available
As a developed market, Australia represents opportunities for risk averse pharmaceutical investors, given its ageing and generally affluent population. Importantly, the government is implementing cost-cutting measures to cope with escalating healthcare costs, therefore generic drugmakers will stand to benefit from the patented to generic drug switch. However, given that generic costs is higher in Australia as compared to other developed countries, a downside risk to the view is the lack of generic substitution, given no apparent benefits to patients.
View full press release